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Abstract: Adjuvants are substances that increase the immune response to a given antigen. In the development of novel vaccine adjuvants/
systems, saponins are one of the most attractive molecules due to their altered immunomodulatory activities. In this study, we tried
to develop PEG (polyethylene glycol)/cholesterol-based lipid nanoparticles (LNPs) to deliver the Astragaloside VII (AST-VII) and
potentiate adjuvant properties of AST-VII for the influenza vaccine. In the formation of PEG/cholesterol/AST-VII-based LNPs
(PEG300: Chol-AST-VII LNPs), 3 different primary solvents (acetone, ethanol, and chloroform) were evaluated, employing their effects
on hydrodynamic particle size, distribution, surface chemistry, and colloidal stability. Prepared nanoparticles were simply admixtured
with inactivated influenza antigen (H3N2) and applied to PMA (phorbol 12-myristate 13-acetate)-ionomycin treated human whole
blood to evaluate their cytokine release profile. PEG300: Chol-AST-VII LNPs (80.2 ± 7.7 nm) were obtained using chloroform as a
desolvation agent. Co-treatment of PMA-ionomycin with AST-VII and PEG300: Chol-AST-VII LNPs significantly increased the levels
of IL-2 and IFN-g, compared to PMA-ionomycin alone. In the presence of H3N2, AST-VII was able to augment IL-17A, while PEG300:
Chol-AST-VII LNPs stimulated the production of IFN-g. Hemolysis was only observed in PEG300: Chol-AST-VII LNPs (250 µg/mL)
treatment. AST-VII and AST-VII-integrated LNPs could be used as efficacious adjuvants for an inactivated H3N2 vaccine in vitro, and
cytokine response through Th1/Th17 route was reported.
Key words: Immunomodulatory activity, nanocarriers, cholesterol, triterpenoid saponins, Astragaloside VII, influenza

1. Introduction
Adjuvants are chemical/biological molecules that increase
the efficacy of vaccines by augmenting the immunogenicity
of weaker immunogens and thereby reduce the amount
of antigen and frequency of immunization required
for protective immunity (Shi et al., 2019; Wang and Xu,
2020). There are many types of vaccines with adjuvants
under clinical trials or in the market that mostly serve as
oil-in-water emulsions and phospholipid formulations
(Ilyinskii et al., 2014). One of the significant challenges in
developing an effective adjuvant carrying formulation that
combines the adjuvant and vaccine is finding the optimal
carrier system that potentiates immune responses and can
ensure the delivery of the cargo with higher bioavailability
(Malyala and Singh, 2009).
Influenza viruses (IVs) are globally important human
respiratory pathogens belonging to the orthomyxovirus
family. These single-stranded and helically-shaped RNA
viruses are divided into 3 main types (A, B, and C) in terms

of nuclear material. IVs were first named in the “Hong
Kong” pandemic (1968) and, since then, they have been
responsible for several particularly significant epidemics
throughout history. Seasonal IVs frequently evolve, and
new strains quickly replace the older. This entails the
need for a periodical update and reassessment of vaccine
effectiveness (Harding and Heaton, 2018).
The development of novel adjuvant systems or the
improvement of adjuvants to promote cellular and humoral
immune response plays a crucial role in providing more
robust protection against IVs. Lipid-based carriers are an
essential class of adjuvant carriers that can encapsulate
both hydrophilic and hydrophobic cargo (Sardan et al.,
2013). Cholesterol is one of the well-known liposomal
components used mostly to increase membrane flexibility
and permeability. Lipid nanoparticles (LNPs) containing
mRNA coding protein antigens have been used to
induce immune response and provide protection against
influenza and Zika viruses in mice (Shirai et al., 2020).
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For this reason, LNPs can be used as an effective delivery
vehicle for peptide/protein antigens and adjuvant in the
vaccine development sector. LNPs have been developed to
deliver immunostimulatory agents such as CpG [Toll Like
Receptor (TLR-9) agonist] (Shirota and Klinman, 2014),
MPL (monophosphoryl lipid A, TLR-4 agonist) (Kedmi
et al., 2010), and small-molecule immune potentiators
targeting TLR-7 (Wu et al., 2014). In LNP production,
saponins are also used due to their immunostimulatory
properties. Saponins are secondary metabolites derived
from plant or marine organisms and have a wide
range of commercial and industrial applications in the
pharmaceutical and food industries. They are characterized
by their aglycones as triterpenoid or steroidal, containing
one or more sugar moieties. Because of their lipid-soluble
aglycone part and water-soluble sugar chains, saponins
are amphiphilic molecules and widely used as surface
active agents. They exhibit diverse biological activities
due to their anti-inflammatory, adjuvant, antifungal, antiparasitic, antioxidant, anti-obesity, antiviral, diuretic,
hemolytic, and neuroprotective properties (Moses et al.,
2014). The capability of saponins to form a complex with
steroids, including cholesterol, has been used to promote
the formation of stable particulates. Immune stimulating
complexes (ISCOMs) are 40–60 nm-sized cage-like
structures composed of cholesterol, phospholipids,
Quillaja saponins, and antigens. ISCOMATRIX differs
from ISCOMs in that the antigen is not integrated into the
structure during its synthesis (Sun et al., 2009; Duewell et
al., 2011). Influenza ISCOM vaccines induced antibody
and cytotoxic T-cell response in mice (Sjölander et al.,
2001).
The crude extract of Astragalus membranaceus has been
used in traditional Chinese medicine to treat the common
cold, influenza, chronic diarrhea, oedema, diabetes
mellitus, and so forth. It is rich in saponins, flavonoids,
polysaccharides, amino acids, and many trace elements
(Ma et al., 2002). Astragaloside VII, a triterpenoid saponin
isolated from several Astragalus species, demonstrated
a Th1/Th2-balanced antibody response along with
the production of Th1 and Th17 related cytokines (i.e.
IL-2, IFN-γ, IL-17A, and TGF-β) and stimulation of
splenocytes to proliferate (Bedir et al., 1999; Nalbantsoy
et al., 2011; Nalbantsoy et al., 2012; Yakuboğulları et al.,
2019). AST-VII, the first tridesmosidic molecule isolated
from natural sources, is highly polar and acid-labile,
and its bioavailability from the gastrointestinal tract is
questionable. Recently, Cano-Sarabia et al. reported a
cholesterol-rich double-layer nanovesicle assembly solid
in the form of CO2-expanded acetone, which is driven
by the presence of a surfactant and is claimed to be more
stable than liposomes (Ferrer-Tasies et al., 2013). However,
this method needs special equipment and can only be
performed under high pressure.

Thus, herein we attempted to optimize a more
straightforward method that could overcome these
constraints and facilitate the formation of the
saponin-cholesterol complexation by solvent-assisted
nanoprecipitation. We developed lipid nanoparticles to
deliver AST-VII in order to increase the immunostimulatory
effects of AST-VII on seasonal influenza (H3N2) in vitro.
Cholesterol, low molecular weight PEG (MW = 300),
and AST-VII were used as the main components of the
nanocarrier system. Acetone, ethanol, and chloroform
were evaluated as primary solvents modulating the
physicochemical properties of the resulting nanoparticles.
The H3N2 subset was chosen as a viral antigen. The in
vitro immunomodulatory effects of AST-VII-integrated
PEG300: Chol nanoformulations (LNPs) were investigated
by evaluating the cytokine release profiles in human whole
blood and also hemolytic activity. These data were later
compared with those of AST-VII and QS-21.
2. Materials and methods
2.1. Materials
RPMI-1640 (Sigma-Aldrich Corp., St. Louis, MO, USA),
PMA (Sigma-Aldrich Corp.), ionomycin (Sigma-Aldrich
Corp.), penicillin-streptomycin (Biological Industries,
Beit Haemek, Israel), fetal bovine serum (Gibco, Thermo
Fisher Scientific Inc.,Waltham, MA, USA), IL-17A, IL2, and IFN-g ELISA kits from eBioscience (Aviscera
Bioscience, Inc., Santa Clara, CA, USA) were used in the
experiments. A/duck/Hokkaido/5/77 H3N2, provided
and given as a gift by from the Avian Influenza OIE /FAO
Reference Lab. of Hokkaido University in Japan, was also
used. Polyethylene glycol (MW=300) PEG, Cholesterol,
PBS (10X), and solvents were purchased from SigmaAldrich Corp.. AST-VII was provided by the Bionorm
Company, İzmir, Turkey.
2.2. Nanocarrier synthesis via the nanoprecipitation
method
The nanoprecipitation method was first conducted to
evaluate 3 solvents (chloroform, acetone, or ethanol)
possessing different polarities for primary solvent and
water as a dispersing phase. Cholesterol (20 mg) and ASTVII (2.5 mg) were dispersed in 1 mL of primary solvent
(chloroform, acetone, or ethanol) and mixed drop-wise
(approximately 50 µL/s each) with preheated PEG300 (5
mg) dissolved in 5 mL Mili-Q water at 70 °C (higher than
the Tg of cholesterol) under vigorous mixing. Resulting
nanocarriers were cooled down to room temperature and
kept in a refrigerator until further use.
2.3. Nanocarrier characterization
Hydrodynamic radius and surface ζ-Pot of the resulting
nanoformulation,
PEG300:
Chol-AST-VII
were
characterized by dynamic light scattering (DLS) using
Nanosizer/Zetasizer Nano-ZS ZEN 3600 (Malvern
Panalytical Inc., Westborough, MA, USA). Results were
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presented as the average and standard error calculated
using at least 3 values obtained from parallel experiments
under the same conditions. The isoelectric point of the
LNPs was determined by measuringζ-Pot values at a
range of pH values between 2–12 via Nano-ZS ZEN 3600
(Malvern Panalytical Inc.). Surface characteristics were
analyzed by Fourier transform infrared spectroscopy
(FTIR) (PerkinElmer, Inc., Waltham, MA, USA). All
samples were dried on support and measured in the
frequency range of 4000 to 450 cm–1 with 4 cm–1 resolution.
Particle morphology was evaluated via a JEOL JEM-1400
120kV, transmission electron microscope (TEM). Particle
contrast was enhanced by uranyl acetate staining [2%
(w/v), 2 min]. AST-VII entrapment efficiency (EE%) of
the prepared LNPs were evaluated by an indirect method.
Approximately 2 mL of the sample was purified through
a Millipore Amicon Ultra-2.0 centrifugal filter unit by
centrifugation of the sample at 7000 rpm for 10 min. The
supernatant containing the free AST-VII was collected,
and samples were immediately analyzed by HPLC. ASTVII was detected following HPLC conditions: Column
Thermo C18: 100 × 4.6 mm, 3 µm; gradient 0–1.50 min
70% water, 30% acetonitrile; 1.50–13 min 45% water
55% acetonitrile; 13–15 min 70% water 30% acetonitrile;
temperature 35 ºC; injection volume 5 μL; flow rate 0.75
mL/min.
2.4. Preparation, isolation, and inactivation of H3N2
Preparation, isolation, and inactivation studies of H3N2
were performed at the Poultry Diseases Diagnosis
Laboratory, Veterinary Control, and Research Institute
in İzmir, Turkey. H3N2 was propagated on 9 to 10-d-old
embryonated SPF (specific pathogen-free) chicken eggs.
The allantoic fluids of the eggs at the end of the incubation
period were collected, centrifuged at 6000 rpm for 10
min, and then tested for hemagglutinating activity. Serial
10-fold dilutions of allantoic fluid were prepared and
injected into embryonated SPF chicken eggs to calculate
EID50 by the Spearman-Karber method (Allan et al.,
1978). The titers of H3N2 were found to be 1:264. H3N2
was inactivated with 8% of BEI (binary ethyleneimine)
(Bahnemann, 1975). The inactivated virus sample was
also inoculated to 5 SPF eggs and incubated for 3–4 days
in order to confirm inactivation. The allantoic fluid was
examined over 3 serial passages in the SPF eggs and tested
by HA (hemagglutination assay) to determine a surviving
virus.
2.5. Peripheral whole-blood cultures
Human whole blood (hWB) and hemolytic activity assays
were assessed using heparinized whole blood obtained
from healthy volunteers (Ege University, Medico-social
Policlinic, İzmir, Turkey). The protocol was approved
by the Human Ethics Committee of Ege University, and
applied procedures conformed to the Declaration of
Helsinki. The subjects were informed about the procedures
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to be followed and signed the informed consent forms (1511/19).
AST-VII and QS-21 were dissolved in saline, and all
preparations were filtered through a 0.22-μM filter. ASTVII, QS-21, and PEG300: Chol-AST-VII LNPs were added
into inactivated H3N2 with simple admixture. Heparinized
whole blood from healthy volunteers was diluted 1:10 with
RPMI-1640 medium, 100 U/mL of penicillin, 100 mg/
mL of streptomycin, and 10% fetal bovine serum. PMA
(50 ng/mL) and ionomycin (400 ng/mL) stimulated hWB
cultures were treated with AST-VII, QS-21, and PEG300:
Chol-AST-VII (1:5:20) at 2 concentrations (3 µg/mL and
6 µg/mL), both in the absence and presence of inactivated
H3N2 (4HA) and incubated at 37 ºC in 5% CO2 for 48 h
(Yesilada et al., 2005). The cell culture supernatants were
collected and stored at –20 ºC for further cytokine analysis.
2.6. Measurement of cytokine production
IFN-γ, IL-2, and IL-17A titers in the cell culture
supernatants were measured using a commercial ELISA kit
(e-Bioscience, Vienna, Austria). The assay was performed
according to the manufacturer’s instructions and in
triplicate. Spectrophotometric analysis was conducted
by measuring the sample absorbance at 450 nm, and
cytokine levels were determined from a standard curve.
The sensitivity of each kit was 2 pg/mL, 4 pg/mL, and 4 pg/
mL for IL-2, IFN-γ, and IL-17A, respectively.
2.7. Hemolytic activity assay
Hemolytic activity assay was performed with human
red blood cells (RBCs) following the methodology of
Nalbantsoy et al. (2011). Blood samples prepared as aliquots
of 7 mL were washed and centrifuged 3 times at 2000×g for
5 min with sterile PBS. The cell suspension was prepared
by diluting the pellet to 0.5% w/v in PBS (10×, pH 7.4).
Approximately 0.01 mL of the cell suspension was mixed
separately with AST-VII, QS-21, and PEG300: Chol-ASTVII LNPs (1:5:20) at varying concentrations (0, 25, 50,
and 250 µg/mL) in 0.05 mL saline solution. The mixtures
were incubated for 30 min at 37 ºC and centrifuged at
800×g for 10 min. The free hemoglobin content of the cell
supernatants was determined by measuring optical density
at 412 nm using a UV spectrophotometer. PBS and distilled
water were defined as minimum and maximum hemolytic
controls. The hemolytic activity (%) was calculated by
following formula= (A412 of RBCs treated samples – A412
of PBS treatment)/(A412 of distilled water treatment – A412
of PBS). Each experiment was run in triplicate at each
concentration.
2.8. Statistical analysis
The data were measured with mean and standard errors,
and the statistical significance of differences was examined
using the Student t-test, one-way ANOVA, and Tamhane’s
T2 as the post hoc test (GraphPad Prism 5.01 and SPSS for
Windows). Statistically significance was determined as *P
< 0.05, **P ≤ 0.01, and ***P ≤ 0.001.
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3. Results and discussion
3.1. Nanocarrier preparation and characterization
Cholesterol-rich nanocarriers were prepared through the
nanoprecipitation method using 3 solvents with different
polarities, boiling points as the primary solvent, and
water as a dispersing phase: Acetone as an aprotic polar
solvent; ethanol as a protic polar solvent; chloroform as a
nonpolar, water-immiscible solvent. As depicted in Figure
1, nanoprecipitation occurred instantaneously upon the
addition of the primary solution to the PEG (in water),
resulting in a whitish emulsion. After 1 h, under argon
air supply, a clear solution was obtained with chloroform,
while opaque white solutions were observed when ethanol
and acetone were used.
Hydrodynamic particle size distribution by intensity
was measured using the DLS method and depicted in
Figure 2. LNPs were prepared in both of the solvents
and showed a polydispersity index below 0.5, attributed
to a homogenous size distribution. In acetone assisted
preparation (Figure 2a), 2 groups of nanoparticle
populations appeared: 1 group with a larger Rh around
300–1000 nm and the other with a lower Rh value
around 132.9 ± 10.1 nm. In ethanol, the Rh of particles
decreased to 169.1 ± 9.8 nm (Figure 2b). In the presence
of chloroform, LNPs at 85.3 ± 6.3 nm with narrower size
distribution [Polydispersity index (PDI = 0.218] were
observed. The resulting LNPs are (Figure 2c) in the same
size range as the Quatsomes reported by Ferrer-Tasies.
(Ferrer-Tasies et al., 2013). Decreased Rh in the presence
of water-immiscible chloroform could be due to solvent
displacement, which generates interfacial turbulence and
leads to nanovesicle formation (Campardelli et al., 2012).
During the displacement, the first aggregates split to form
nanodroplets, and once the solvent migrated through
the water, they transformed into nanocarriers; when the
displacement rate was faster, the nanocarrier size was
smaller, which is consistent with results reported here.
The effect of different primary solvents on the ζ-Pot
and the isoelectric point of LNPs are shown in Figure 2d.
Contrary to the highly positive ζ-Pot values of cholesterolrich nanocarriers reported in the literature (Cano-Sarabia
et al., 2009), the LNPs prepared here showed a surface with
a highly negative ζ-Pot. This pronounced difference may be
evidence of the integration of AST-VII and PEG molecules
with the arrangement of oxygen-rich surface functional
groups approaching the cholesterol-based membrane
surface. The ζ-Pot of PEG300: Chol-AST-VII LNPs
synthesized via ethanol, and chloroform (–56.9 and –56.3
mV, respectively) was quite similar to each other except for
PEG300: Chol-AST-VII LNPs prepared with acetone that
had a higher ζ-Pot value (–69.8 mV), indicating that the
charge density significantly depends on the solvent.
Figures 2d and 2e showed the average zeta potential
(ζ-Pot) and hydrodynamic radius (Rh) of prepared

PEG300: Chol-AST-VII LNPs as a function of pH.
Similarly, the difference in particle surface chemistry due
to the desolvating agent affected their surface response to
varying pHs (pH 4–11). The isoelectric point (pI) for each
sample was calculated by the polynomial fitting of the data
plotted in Figure 2d (ζ-Pot values versus pH). The pI value of
nanocarriers prepared in acetone, ethanol, and chloroform
was 5.15, 3.12, and 4.71, respectively. As presented in
Figure 2e, the Rh of LNPs prepared in acetone as a primary
solvent did not show significant pH dependence. The Rh
of PEG300: Chol-AST-VII LNPs prepared in chloroform
decreased with increased alkalinity. That could be
explained by a favored electrostatic repulsion at higher pH
values. On the contrary, when LNPs formed in ethanol,
particle size increased simultaneously with increasing pH.
The arrangement of PEG and AST-VII throughout the
cholesterol membrane resulted in a less soluble surface at
acidic medium; therefore, at lower pHs, the hydrophobic
effect dominates protonation, and nanocarriers shrink
as a result (Chen and Du, 2013). As shown in Figure 3a,
no flocculation or precipitation was observed in either of
the samples after storage at 25 °C for 2 weeks; the samples
remained dispersed in the liquid and did not settle out.
Figure 3b shows the morphology of PEG300: CholAST-VII LNPs prepared using the chloroform that has
the lowest nanocarrier Rh with narrower size distribution.
As indicated in Figures 1 and 2c, PEG300: Chol-AST-VII
LNPs displayed a uniformly distributed particle size with
semispherical geometry. A membrane with a thickness of
4–5 nm corresponds to a bilayer membrane (Genç et al.,
2009; Ferrer-Tasies et al., 2013).
As disclosed in Figure 3b, the Rh of PEG300: CholAST-VII LNPs matched the average diameter shown in
Figure 2c. Besides this, Figure 3b demonstrates a thick
surface layer comprising of a hollow internal region.
The surrounding shadows of PEG300: Chol-AST-VII
LNPs were made up of uranyl acetate, which was used
for a sharper contrast between the nanocarriers and the
background.
In order to assess the particle surface chemistry, FTIR analyses of liquid samples were performed. IR spectra
of the pristine, AST-VII, and nanocarriers, obtained
using different primary solvents, are shown in Figure 3c.
As expected, they all showed several characteristic bands
of the AST-VII, PEG, and cholesterol (Figure 3d). The
broad transmission band centered around 3400 cm–1, was
assigned to the hydrogen-bonded hydroxyl groups of both
AST-VII and cholesterol, and became less prominent in
self-assembled carriers. More importantly, a shoulder
band with a stronger absorbance peak appeared at slightly
lower frequencies (~3220 cm–1) (Figure 3d). This can be
presumed as evidence of the interassociated hydrogen
bonds formed between each component (Salim et al.,
2013). The increased transmittance in this region also
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Figure 1. Schematic illustration of the synthesis route applied for the formation of PEG300: Chol-AST-VII LNPs through the
nanoprecipitation method in the presence of solvent/water interphase. TEM image of an as-synthesized nanovesicle and magnified
image of the nanovesicle membrane.

Figure 2. DLS results of PEG300: Chol-AST-VII LNPs. Hydrodynamic particle size distribution by intensity graph of PEG300: CholAST-VII LNPs made using (a) acetone; (b) ethanol; and (c) chloroform as a primary solvent for the nanoprecipitation method.
Dependence of (d) ζ-Potential and (e) hydrodynamic size of nanocarriers on the pH and primary solvent type.
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reflects the decreased hydrophilicity of the surface. The
reduced intensity of the main bands of AST-VII assigned
to alkyl groups (2700–3000 cm–1), together with the
disappearance of the C-H bend at 1039 cm–1, demonstrates
that AST-VII was embedded through the cholesterol
membrane by hydrophobic carbonaceous groups (Figures
3c and 3d). The same IR profiles were present for all the
nanocarrier suspensions with changing transmittance
regardless of the solvent used (Figure 3c). A proposed
nanocarrier configuration with each component of the
formulation is represented in Figures 4a and 4b. PEG300:
Chol-AST-VII LNPs with the lowest size distribution and
opacity were observed when nanocarriers were prepared
using chloroform, therefore further in vitro studies were
pursued with those carriers. The AST-VII entrapment
efficiency of the LNPs was determined as 65 ± 5.3% with
the HPLC method.
3.2. Evaluation of cytokine response induced by PEG300:
Chol-AST-VII LNPs adjuvanted H3N2 vaccines in vitro
A comparative analysis of PEG300: Chol-AST-VII LNPs
on human whole blood (hWB) was conducted to screen
the cytokine profile (IL-2, IFN-γ and IL-17A) and a
possible type of immune response towards Th1/Th2/Th17.
IL-2 is a Th1 type cytokine and does not have direct
antiviral activity; however, it has an essential role in the
modulation of many immunologic events by stimulating
the rapid proliferation of T-cells (Liao et al., 2013). As
shown in Figure 5a, IL-2 levels significantly changed when
cells were exposed to 6 µg/mL AST-VII (P < 0.05) and QS21 (P ≤ 0.01). The IL-2 level in the PEG300: Chol-ASTVII LNPs (3 µg/mL) treatment group was 1.12-fold higher
than the PMA-ionomycin treatment, which was also
higher than the AST-VII (1.14 fold) treatment. When cells
were exposed to the H3N2 vaccine mixed with AST-VII
at 6 µg/mL (P ≤ 0.001) and PEG300: Chol-AST-VII LNPs
at both concentrations [3 µg/mL (P < 0.05) and 6 µg/mL
(P ≤ 0.001)], IL-2 levels dropped in comparison to PMAionomycin. The decrease was as high as 3.85-fold for ASTVII treated cells, while encapsulation of AST-VII in LNPs
backbone decreased this influence to 1.4-fold (3 µg/mL)
and 1.77-fold (6 µg/mL), respectively. Inactivated H3N2
(4HA) alone also decreased the IL-2 titers by 1.3-fold (P
≤ 0.01), compared to PMA-ionomycin. These results show
that the integration of AST-VII into a nanocontainer
reduced the immune-suppressive properties of influenza
regarding H3N2 combined with AST-VII alone. There
are many reports demonstrating a similar retardation or
passivation effect of nanoparticles by a slow-release that
could be useful for preventing or controlling the immunesuppressive properties of therapeutic cargo (Higaki et al.,
2005).
IFN-γ is produced by Th1 and NK cells and is direct
evidence of its antiviral effect (Han and Meydani, 2000). As

depicted in Figure 5b, treatment of AST-VII (6 µg/mL; P ≤
0.01) and QS-21 (3 µg/mL; P ≤ 0.001; 6 µg/mL: P ≤ 0.001)
promoted IFN-γ secretion significantly in respect to PMAionomycin. PEG300: Chol-AST-VII LNPs alone did not
affect IFN-γ levels at the concentrations of 3 and 6 µg/mL,
whereas mixing PEG300: Chol-AST-VII LNPs (3 µg/mL)
with inactivated H3N2 substantially elevated IFN-γ levels
by 1.25-fold (P ≤ 0.001). The increased concentration of
PEG300: Chol-AST-VII LNPs to 6 µg/mL decreased the
IFN-γ concentration to the levels expressed by AST-VII
(6 µg/mL) alone. Depletion of the IFN-γ titers (P ≤ 0.001)
occurred in the presence of AST-VII (6 µg/mL), and the
inactivated H3N2 mixture was 3.32 times higher than
H3N2 alone (P < 0.05). It is already known that cationic
cholesterol combined with split inactivated influenza
vaccines displayed remarkable adjuvant properties in mice
and macaques (Guy, 2007). The aforementioned result
might be related to the presence of cholesterol and its
ability to produce IFN-γ, but the dominant mechanism for
our formulation has yet to be elucidated (Barnier-Quer et
al., 2013).
IL-17A is a proinflammatory cytokine produced by
Th17 cells, CD8+ T cells, NKT cells, neutrophils, and
macrophages and acts as an inflammation mediator (Xu
and Cao, 2010). As shown in Figure 5c, no significant
augmentation in IL-17A levels was observed even at the
highest concentrations of AST-VII, PEG300: Chol-ASTVII LNPs, or QS-21. When the cells were co-treated
with AST-VII and PEG300: Chol-AST-VII LNPs at
concentrations of 3 and 6 µg/mL and inactivated H3N2,
IL-17A titers significantly decreased 5.2-fold, 44-fold,
7-fold, and 8.5-fold, compared to the PMA-ionomycin
treated group, respectively (P ≤ 0.001).
PEG300: Chol-AST-VII LNPs revealed a similar
response with the LNPs against IVs in the literature that
promoted the production of Th1 cytokines, IL-2, and
IFN-g but suppressed the IL-17A response compared to
PMA-ionomycin. The cationic liposome adjuvant system
(CAF01), containing trehalose 6,6’-dibehenate (TDB) and
dimethyldioctadecylammonium (DDA), combined with
trivalent influenza vaccine (TIV), enhanced influenzaspecific serum antibody titers and Th1/Th17 immune
response in terms of IL-1b, IL-2, IL-12, IFN-g, TNF-a, and
IL-17 secretions in vivo (Davidsen et al., 2005; Rosenkrands
et al., 2011). ISCOMATRIX, an LNP containing saponin
compound, elicited a Th1/Th2 mixed immune response
(IL-2, IFN-g and IL-4) in mice. Also, administration of
ISCOMATRIX with influenza promoted high antibody
titers and a CD4+ T-cell response (Morelli et al., 2012).
Figure 6 illustrates the possible action mechanism of
PEG300: Chol-AST-VII LNPs in terms of IL-2 and IFN-g
secretion.
We speculate that the influenza virus alters antibody
production, T lymphocyte activation, and neutrophil
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Figure 3. TEM and FTIR analysis of LNPs. (a) images of PEG300: Chol-AST-VII nanocarriers prepared using different primary
solvents before and after storage at room temperature over 15 min. No precipitation was observed over time; (b) transmission electron
microscope image of PEG300: Chol-AST-VII LNPs made up using chloroform as a primary solvent; (c) FT-IR spectra of AST-VII
integrated nanocarriers prepared using chloroform (red line), acetone (blue line), and ethanol (green line), spectra corresponding to (d)
PEG300: Chol-AST-VII LNPs prepared in chloroform/water (i) and each component of LNPs: cholesterol (ii), Polyethylene glycol (iii),
and AST-VII (iv). The characteristic peaks of each component are illustrated by asterisks (*); the arrow points to the interassociated
hydrogen bonds formed by carrier formation.

Figure 4. Chemical representation of each component of LNPs. a) AST-VII, cholesterol and polyethylene glycol; b) schematic
representation of LNP formation in chloroform/water interphase.
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Figure 5. Cytokine profile of adjuvants and adjuvanted H3N2. Cytokine levels of PMA-ionomycin stimulated hWB treated with ASTVII, QS-21, and PEG300: Chol-AST-VII LNPs mixed w/without inactivate H3N2. The cell culture supernatants were analyzed for a)
IL-2; b) IFN-γ; and c) IL-17A by ELISA. The significant difference is defined between treated groups and PMA-ionomycin: *P < 0.05,
**P < 0.01, ***P < 0.001.

Figure 6. Schematic representation of the possible mechanism of action for PEG300: Chol-AST-VII LNPs. Inactivated H3N2 vaccine
combined with AST-VII-carrying LNPs, and this combination was taken by APC (i). After internalization of the adjuvant-antigen
combination, APC (immature state) was processed and presented the viral antigens on the MHC molecules (mature state-activated) (ii)
to naïve CD8+ and CD4+ T-cells (iii). Activated T-cells secreted Th1 type cytokines (i.e. IL-2, IFN-g).
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function due to its immunosuppressive properties. Thus,
it possibly caused a decrease in phagocytosis, loss of
alveolar macrophages, and production/suppression of a
variety of cytokines such as IL-10, which is associated with
down-regulation of Th1 cytokines such as IL-2 and IFN-γ
(McCullers, 2006). Besides, a conserved motif in the fusion
peptide of influenza hemagglutinin could be responsible
for its immunosuppressive properties, affecting cytokine
expression, production of TNF-α, IFN-β, IFN-γ, and
inhibition of type I IFN pathway (Marcus et al., 2005). EGR2
(early growth response) is a transcriptional factor and has
an essential role in the differentiation of naive T-cells and
the regulation of antigen-specific immune responses to the
influenza viral infection. T-cells originating from EGR2
conditional knockout mice exhibited a decrease in IFN-γ,
TNFα, and IL-2 levels (Du et al., 2014).
Activated T-cells proliferated and differentiated into
effector T-cells, which produced cytokines (i.e. IL-2 and
IFN-γ) or chemokines, depending on the nature of the
antigen.
Our results suggest that LNPs delay or decrease the
immunosuppressive properties of the IVs by significantly
reversing the inhibitory effect of H3N2 and altering IFN-γ
secretion. Therefore, another mechanism related to the
influenza immunosuppression could be related to EGR2
signaling, and further studies may exhibit the impact of
PEG300: Chol-AST-VII LNPs on this pathway.
3.3. Hemolytic activity
Hemolytic activity was investigated by treating human
RBCs with AST-VII, QS-21, and PEG300: Chol-ASTVII LNPs at varying concentrations (25, 50, and 250
µg/mL). As shown in the Table, AST-VII had few or no

hemolytic activity, while the same concentrations of QS21 caused higher hemolysis. AST-VII-carrying LNPs, on
the other hand, displayed hemolytic activity only at the
highest concentrations (250 µg/mL, 112.10%). PEGylation
is a widely used method to overcome the solubility
and hemolytic activity problems of drugs (Alayoubi et
al., 2013). The bulky PEG head groups on the surface
of nanoemulsions prevent interactions with the cell
membrane and thus reduce hemolysis (Jumaa et al., 1999).
An excess amount of cholesterol in LNPs could prevent the
interaction of saponins with cell membrane cholesterols
and eventually reduce the hemolysis.
In conclusion, this study attempted to develop a new
adjuvant delivery system that is effective towards cellmediated immune response. Self-assembled nanocarriers
were designed, taking into account the complexation
capacities of saponins with cholesterol. Co-treatment
of H3N2 with AST-VII-carrying LNPs induced a higher
Th1 response by increasing IL-2 and IFN-γ levels and
suppressing IL-17A. Moreover, a minimized hemolysis
profile was obtained by PEG300: Chol-AST-VII LNPs
compared to QS-21. The data reported here suggest the
potential of LNPs to deliver AST-VII and activate Th1mediated cytokines against H3N2.
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Table. Hemolytic activity of AST-VII, QS-21, and PEG300: Chol-AST-VII LNPs in different
concentrations. Minimal and maximum hemolytic control was defined as PBS and distilled
water, respectively. Significance level was defined as *P < 0.05, ***P ≤ 0.001.
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Groups

Absorbance value Hemolytic activity (%)

PBS

0.1104 ± 0.0010

0.00 ± 0.1880

Distilled water

0.6387 ± 0.0005

99.9937 ± 0.0892

AST-VII (250 µg/mL)

0.1217 ± 0.0012

2.1326 ± 0.2361*

AST-VII (50 µg/mL)

0.1210 ± 0.0022

2.0064 ± 0.4089

AST-VII (25 µg/mL)

0.0873 ± 0.0021

–4.3662 ± 0.3889

QS-21 (250 µg/mL)

0.8737 ± 0.0058

144.4760 ± 1.0965***

QS-21 (50 µg/mL)

0.7857 ± 0.0039

127.8188 ± 0.7304***

QS-21 (25 µg/mL)

0.5147 ± 0.0104

76.5222 ± 1.9691*

PEG300: Chol-AST-VII LNPs (250 µg/mL) 0.7027 ± 0.0050

112.1080 ± 0.9443***

PEG300: Chol-AST-VII LNPs (50 µg/mL)

0.0881 ± 0.0063

–4.2148 ± 1.1966

PEG300: Chol-AST-VII LNPs (25 µg/mL)

0.0719 ± 0.0096

–7.2812 ± 1.8134
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Informed consent
The protocol for human whole blood assay was approved
by the Human Ethics Committee of Ege University and
applied procedures conformed to the Declaration of

Helsinki. The subjects were informed about the procedures
to be followed and signed the informed consent forms
accordingly (15-11/19).
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